This funding call has closed
Applications closed on 5 June 2026. The details below are kept for reference, and the funder may run this scheme again.
SPARK NS Translational Research Program, 2027 Cohort – SPARK NS is now accepting applications from academic researchers developing therapeutics for autism and Parkinson’s disease for the 2027 Cohort of our translational research program. Selected projects will receive milestone-based funding of up to $2,000,0001 and extensive support in all aspects of translational research and drug development. The deadline to apply is June 5, 2026, at 5:00 pm PT.
Eligibility
SPARK NS accepts applications for the SPARK NS Translational Research Program from principal investigators with projects focused on developing therapeutics for autism, Parkinson’s disease, and adjacent disorders at academic or nonprofit research institutions in the United States, Canada, the United Kingdom, and Europe. We do not accept projects aimed at developing medical devices. We only accept projects that include diagnostics if they are in support of a proposed therapeutic. We value diversity and are committed to creating an inclusive research environment. Applicants from all backgrounds and experiences are encouraged to apply.
Visit funding web page
(https://sparkns.org/call-for-proposals/)